In his new role, Dr. Tavecchio will be leading R&D activities related to NeuroVive's discovery programs, working closely with CSO Eskil Elmér, CMO Magnus Hansson, and the core research team of scientists at NeuroVive. Dr. Tavecchio holds a PhD in Cancer Pharmacology from the Mario Negri Institute for Pharmacological Research in Milan and has authored over 20 scientific publications. Most recently he comes from a position as Associate Staff Scientist at Wistar Institute in Philadelphia, USA, where his research activities have been focused on the involvement of ciclophilin D in various aspects of metabolic diseases and cancer.
“We are extremely happy to be able to add Dr. Tavecchio to our research team. His research expertise in the ciclophilin D area and related metabolic effects fits hand in glove with NeuroVive’s project portfolio. In combination with his extensive knowledge within the oncology area, Dr. Tavecchio’s primary task for NeuroVive will be to explore new therapeutic opportunities for the company’s ciclophilin inhibitor compounds”, said Eskil Elmér, CSO NeuroVive.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.
NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to neurological and metabolic diseases such as NASH.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or email@example.com
Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or firstname.lastname@example.org
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on November 8, 2016.